2.50
Hdl Handle:
http://hdl.handle.net/10755/149527
Type:
Presentation
Title:
Predictors of antineoplastic chemotherapy nausea and vomiting
Abstract:
Predictors of antineoplastic chemotherapy nausea and vomiting
Conference Sponsor:Sigma Theta Tau International
Conference Year:1991
Author:Rhodes, Verna, EdS
P.I. Institution Name:University of Missouri – Columbia
Title:Associate Professor
Postchemotherapy nausea and vomiting are disruptive and distressing

symptoms that affect the quality of life, discourage the

continuation of treatment, and present individual and corporate

economic implications. The purpose of this presentation is to

describe variables that predict postchemotherapy nausea and

vomiting during six cycles of initial selected chemotherapy

regimens. A stratified sample of subjects (N = 324), 21 to 84

years of age, were selected from two geographic regions in two

Midwestern states. Tools used were the Adapted Symptom Distress

Scale (ASDS), the Rhodes Index of Nausea and Vomiting (INV), and

the Symptom Experience and Expectation Interview Schedule (SEEIS).

Cronbach's alpha for the ASDS was .90 to .96 and for the INV was

.89 to .97. The SEEIS was composed of five questions to solicit

past nausea and vomiting experience and to assess symptom

expectation. A SAS stepwise regression model was used to test the

following hypothesis: patterns of nausea and vomiting will be

related to chemotherapy (CT) drug protocol, age, gender, prior

experience with symptoms, and symptom expectation. Findings were

that three drug protocols account for 17 percent of the variance in

the total nausea and vomiting score and were predictive of the Cycle

1 total nausea score; that age, the three CT drug protocols, prior

nausea frequency, gender, and the nausea symptom expectation

accounted for 19 percent of the variance and were the best predictors

of nausea; and that 22 percent of the variance in total vomiting

can be predicted using the three CT drug protocols and age. Age was

inversely related to vomiting. Profiles of patients most likely to

experience higher levels of postchemotherapy nausea and/or vomiting

were developed and will be discussed in light of self-regulation

theory and specific nursing practice recommendations will be made.



Repository Posting Date:
26-Oct-2011
Date of Publication:
17-Oct-2011
Sponsors:
Sigma Theta Tau International

Full metadata record

DC FieldValue Language
dc.typePresentationen_GB
dc.titlePredictors of antineoplastic chemotherapy nausea and vomitingen_GB
dc.identifier.urihttp://hdl.handle.net/10755/149527-
dc.description.abstract<table><tr><td colspan="2" class="item-title">Predictors of antineoplastic chemotherapy nausea and vomiting</td></tr><tr class="item-sponsor"><td class="label">Conference Sponsor:</td><td class="value">Sigma Theta Tau International</td></tr><tr class="item-year"><td class="label">Conference Year:</td><td class="value">1991</td></tr><tr class="item-author"><td class="label">Author:</td><td class="value">Rhodes, Verna, EdS</td></tr><tr class="item-institute"><td class="label">P.I. Institution Name:</td><td class="value">University of Missouri &ndash; Columbia</td></tr><tr class="item-author-title"><td class="label">Title:</td><td class="value">Associate Professor</td></tr><tr><td colspan="2" class="item-abstract">Postchemotherapy nausea and vomiting are disruptive and distressing<br/><br/>symptoms that affect the quality of life, discourage the<br/><br/>continuation of treatment, and present individual and corporate<br/><br/>economic implications. The purpose of this presentation is to<br/><br/>describe variables that predict postchemotherapy nausea and<br/><br/>vomiting during six cycles of initial selected chemotherapy<br/><br/>regimens. A stratified sample of subjects (N = 324), 21 to 84<br/><br/>years of age, were selected from two geographic regions in two<br/><br/>Midwestern states. Tools used were the Adapted Symptom Distress<br/><br/>Scale (ASDS), the Rhodes Index of Nausea and Vomiting (INV), and<br/><br/>the Symptom Experience and Expectation Interview Schedule (SEEIS).<br/><br/>Cronbach's alpha for the ASDS was .90 to .96 and for the INV was<br/><br/>.89 to .97. The SEEIS was composed of five questions to solicit<br/><br/>past nausea and vomiting experience and to assess symptom<br/><br/>expectation. A SAS stepwise regression model was used to test the<br/><br/>following hypothesis: patterns of nausea and vomiting will be<br/><br/>related to chemotherapy (CT) drug protocol, age, gender, prior<br/><br/>experience with symptoms, and symptom expectation. Findings were<br/><br/>that three drug protocols account for 17 percent of the variance in<br/><br/>the total nausea and vomiting score and were predictive of the Cycle<br/><br/>1 total nausea score; that age, the three CT drug protocols, prior<br/><br/>nausea frequency, gender, and the nausea symptom expectation<br/><br/>accounted for 19 percent of the variance and were the best predictors<br/><br/>of nausea; and that 22 percent of the variance in total vomiting<br/><br/>can be predicted using the three CT drug protocols and age. Age was<br/><br/>inversely related to vomiting. Profiles of patients most likely to<br/><br/>experience higher levels of postchemotherapy nausea and/or vomiting<br/><br/>were developed and will be discussed in light of self-regulation<br/><br/>theory and specific nursing practice recommendations will be made.<br/><br/><br/><br/></td></tr></table>en_GB
dc.date.available2011-10-26T10:04:12Z-
dc.date.issued2011-10-17en_GB
dc.date.accessioned2011-10-26T10:04:12Z-
dc.description.sponsorshipSigma Theta Tau Internationalen_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.